Key result
Polypharmacy and having three or more comorbidities were associated with a higher risk for clinically significant statin-drug interactions.
Why the study?
Statins are widely used in combination with other medications, which may increase the risk of statin-drug interactions.
What are the prevalence and predictors of clinically significant statin-drug interactions among patients taking statins for cardiovascular disease prevention?
Cross-Sectional
Yes
What are the prevalence and predictors of clinically significant statin-drug interactions among patients taking statins for cardiovascular disease prevention?
Polypharmacy and multiple comorbidities significantly increase the risk of clinically significant statin-drug interactions, highlighting the need for routine screening before prescribing.
Answers are grounded in this paper and cite their sources.
Supports screening for statin interactions in polypharmacy or multimorbid patients; hypothesis-generating pending prospective validation.
BACKGROUND: Statins are extensively used in clinical practice for the primary and secondary prevention of cardiovascular diseases. Statins are usually taken in combination with other medications. This may increase the risk of statin-drug interactions. The study aimed to evaluate the prevalence, patterns, and predictors of clinically significant statin-drug interactions among patients on statin therapy. MATERIAL AND METHODS: A cross-sectional study was conducted at the cardiology, endocrine, and internal medicine outpatient clinics in four tertiary care hospitals in Sana'a, Yemen. Lexicomp Drug Interaction database was used to analyze the prescriptions for potential statin-drug interactions. Binary and multivariable logistic regression were utilized for analysis. CONCLUSION: Patients with polypharmacy and those with three or more comorbidities had a higher risk for statin-drug interactions. Therefore, routine screening by physicians and pharmacists for potential interactions should occur before prescribing or dispensing any medication to avoid clinically significant statin-drug interactions.
No takes yet. Share an insight, caveat, or question.
Al-Ashwal et al. (2022) conducted a cross-sectional in Cardiovascular disease (primary and secondary prevention). Polypharmacy and multiple comorbidities was evaluated on Clinically significant statin-drug interactions (p=<0.001). Polypharmacy and having three or more comorbidities were associated with a higher risk for clinically significant statin-drug interactions.
Synapse has enriched 10 related papers. Consider them for comparative context: